PT  - JOURNAL ARTICLE
AU  - Postel-Vinay, Sophie
AU  - Lam, Vincent K
AU  - Ros, Willeke
AU  - Bauer, Todd M
AU  - Hansen, Aaron R
AU  - Cho, Daniel C
AU  - Stephen Hodi, F
AU  - Schellens, Jan H M
AU  - Litton, Jennifer K
AU  - Aspeslagh, Sandrine
AU  - Autio, Karen A
AU  - Opdam, Frans L
AU  - McKean, Meredith
AU  - Somaiah, Neeta
AU  - Champiat, Stephane
AU  - Altan, Mehmet
AU  - Spreafico, Anna
AU  - Rahma, Osama
AU  - Paul, Elaine M
AU  - Ahlers, Christoph M
AU  - Zhou, Helen
AU  - Struemper, Herbert
AU  - Gorman, Shelby A
AU  - Watmuff, Maura
AU  - Yablonski, Kaitlin M
AU  - Yanamandra, Niranjan
AU  - Chisamore, Michael J
AU  - Schmidt, Emmett V
AU  - Hoos, Axel
AU  - Marabelle, Aurelien
AU  - Weber, Jeffrey S
AU  - Heymach, John V
TI  - First-in-human phase I study of the OX40 agonist GSK3174998 with or without pembrolizumab in patients with selected advanced solid tumors (ENGAGE-1)
AID  - 10.1136/jitc-2022-005301
DP  - 2023 Mar 01
TA  - Journal for ImmunoTherapy of Cancer
PG  - e005301
VI  - 11
IP  - 3
4099  - http://jitc.bmj.com/content/11/3/e005301.short
4100  - http://jitc.bmj.com/content/11/3/e005301.full
SO  - J Immunother Cancer2023 Mar 01; 11
AB  - Markup server — Error Not Found The page you were trying to reach could not be found. Please check the address for the page you were trying to reach. If you believe you have reached this page in error, you may contact us with any questions.